Welcome to our dedicated page for Matinas BioPharma Holdings news (Ticker: $MTNB), a resource for investors and traders seeking the latest updates and insights on Matinas BioPharma Holdings stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Matinas BioPharma Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Matinas BioPharma Holdings's position in the market.
Rhea-AI Summary
Matinas BioPharma announces alignment with the FDA on the design of a Phase 3 trial for MAT2203 in patients with invasive aspergillosis. The trial aims to provide a step-down treatment option for adults with limited or no treatment choices, focusing on all-cause mortality and treatment-related toxicities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.91%
Tags
-
Rhea-AI Summary
Matinas BioPharma (NYSE American: MTNB) announces CEO Jerome D. Jabbour will present a company overview at the Biotech Showcase 2024. The presentation will be available via webcast on the company's website. Institutional investors can schedule meetings with management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.78%
Tags
-
Rhea-AI Summary
Matinas BioPharma Holdings, a clinical-stage biopharmaceutical company (NYSE American: MTNB), reports successful oral delivery of LNC-formulated small single-strand oligonucleotides targeting key inflammatory cytokines TNFα and IL-17A in acute colitis and psoriasis models, showing significant reductions in serum TNFα levels and tissue IL-17A mRNA, with improvements in clinical disease markers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.3%
Tags
Rhea-AI Summary
Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) receives positive feedback from FDA on Phase 3 study design for MAT2203, moving closer to full alignment with FDA. Partnership discussions ongoing. Meeting with FDA planned in early 2024 to finalize Phase 3 protocol.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.82%
Tags
-
Rhea-AI Summary
MTNB: Matinas BioPharma reports positive FDA feedback on MAT2203 Phase 3 program for invasive aspergillosis, acknowledging LPAD pathway potential. Oral LNC formulation of docetaxel shows comparable tumor reduction to IV-docetaxel in preclinical model.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.32%
Tags
-
Rhea-AI Summary
Matinas BioPharma Holdings, Inc. announces positive results from an in vivo animal study of an oral LNC formulation of docetaxel, showing reductions in tumor size comparable to IV docetaxel and no systemic toxicity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.98%
Tags
Rhea-AI Summary
Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) will report its third quarter 2023 financial results after market close on November 8, 2023. The company will host an investment community conference call and webcast at 4:30 p.m. Eastern time to discuss the results and provide a business update. Dial-in information is available for the call and the webcast will be archived on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.57%
Tags
-
Rhea-AI Summary
Matinas BioPharma announces complete clinical resolution of patient's recurrent hemorrhagic cystitis with MAT2203
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
313.55%
Tags
-
Rhea-AI Summary
Matinas BioPharma to present at investment conferences on October 12 and October 19, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.52%
Tags
Rhea-AI Summary
Matinas BioPharma announces that MAT2203, its oral LNC formulation of amphotericin B, will be featured in a company pipeline presentation at IDWeek. The presentation will highlight clinical evidence supporting the ability of MAT2203 to improve outcomes for patients with fungal infections. MAT2203 reduces systemic toxicity and has the additional benefit of oral administration. The data presented at IDWeek support the development of an ideal antifungal agent.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.38%
Tags
Matinas BioPharma Holdings, Inc.
NYSE:MTNB
MTNB Rankings
MTNB Stock Data
42.79M
211.96M
2.53%
10.43%
1.51%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
BEDMINSTER
About MTNB
matinas biopharma (nyse mkt: mtnb) is a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications. the company's proprietary, disruptive technology utilizes lipid-crystal nano-particle cochleates to nano-encapsulate existing drugs, making them safer, more tolerable, less toxic and orally bioavailable. the company's lead drug candidate mat2203, currently in phase 2, is an orally-administered, encochleated formulation of amphotericin b (a broad spectrum fungicidal agent). the company has an open investigational new drug (ind) application for mat2501, currently in phase 1, which is an orally-administered, encochleated formulation of amikacin (a broad spectrum aminoglycoside antibiotic agent) for acute bacterial infections, including non-tuberculous mycobacterium (ntm) and multi-drug resistant gram negative bacterial infections. the company's lead anti-infective product candidates, mat2203 and mat2501, position matinas biopharma to bec